AbbVie (NYSE:ABBV) Receives “Overweight” Rating from Piper Sandler

Posted by Tammy Falkenburg on Jun 23rd, 2026

AbbVie (NYSE:ABBV – Get Free Report)‘s stock had its “overweight” rating reiterated by stock analysts at Piper Sandler in a report released on Tuesday,Benzinga reports. They currently have a $298.00 price target on the stock. Piper Sandler’s price objective suggests a potential upside of 27.32% from the stock’s current price.

ABBV has been the topic of several other reports. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Monday, June 8th. Royal Bank Of Canada initiated coverage on shares of AbbVie in a report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 target price for the company. Canaccord Genuity Group increased their target price on shares of AbbVie from $265.00 to $273.00 and gave the stock a “buy” rating in a research note on Tuesday. Morgan Stanley raised their price target on AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Finally, Bank of America raised AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective for the company in a research note on Thursday, April 30th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $253.81.

Get Our Latest Analysis on AbbVie

AbbVie Trading Up 1.8%

NYSE:ABBV traded up $4.04 during midday trading on Tuesday, hitting $234.05. 2,559,915 shares of the company were exchanged, compared to its average volume of 6,738,866. AbbVie has a fifty-two week low of $181.73 and a fifty-two week high of $244.81. The company has a market capitalization of $413.52 billion, a PE ratio of 115.22, a price-to-earnings-growth ratio of 0.66 and a beta of 0.32. The company has a fifty day simple moving average of $212.53 and a 200 day simple moving average of $218.76.

AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The business had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business’s revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.46 earnings per share. As a group, equities research analysts expect that AbbVie will post 14.3 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Chelsea Counsel Co. acquired a new position in AbbVie during the third quarter worth $26,000. Litman Gregory Wealth Management LLC purchased a new position in shares of AbbVie in the fourth quarter valued at $28,000. Westend Capital Management LLC purchased a new position in shares of AbbVie in the fourth quarter valued at $29,000. Imprint Wealth LLC raised its stake in shares of AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after buying an additional 45 shares during the last quarter. Finally, Texas Capital Bancshares Inc TX acquired a new position in shares of AbbVie during the 3rd quarter worth $31,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: AbbVie agreed to buy Apogee Therapeutics for about $10.9 billion in cash, adding promising immunology and inflammation assets to its pipeline and reinforcing its growth strategy. Reuters: AbbVie strikes $10.9 billion deal for Apogee Therapeutics
Positive Sentiment: AbbVie won expanded European approvals for SKYRIZI and MAVIRET, including SKYRIZI for pediatric plaque psoriasis and MAVIRET for acute hepatitis C, which could widen adoption and support international sales. MarketWatch: AbbVie Gets Expanded European Approvals for Skyrizi, Maviret
Positive Sentiment: Allergan Aesthetics, an AbbVie company, received Canadian approval for Boey, a new botulinum neurotoxin for glabellar lines, adding another commercial opportunity in aesthetics. PR Newswire: Allergan Aesthetics receives approval for Boey in Canada

AbbVie Company Profile

(Get Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.